{"product_name":"Nevisense","company_name":"SciBase","product_url":"https://scibase.com/us/","company_url":"https://scibase.com","related_urls":["https://www.prnewswire.com/news-releases/scibase-reaches-milestone-with-over-300-000-patients-tested-with-nevisense-302465743.html","https://www.prnewswire.com/news-releases/scibase-launches-next-generation-nevisense-302426598.html","https://www.prnewswire.com/news-releases/scibase-announces-sale-of-nevisense-to-nih-us-302261009.html","https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices"],"product_code":"SW0612","summary":"Nevisense is a non-invasive diagnostic device developed by SciBase, utilizing advanced Electrical Impedance Spectroscopy (EIS) combined with artificial intelligence to enhance the early detection of skin cancers, particularly melanoma, at the point of care.","description":"Nevisense is a point-of-care diagnostic device that employs Electrical Impedance Spectroscopy (EIS) technology integrated with artificial intelligence to assess suspicious pigmented skin lesions. It provides clinicians with objective, actionable data to support early detection and management of skin cancers, including melanoma and non-melanoma types. The device is FDA-approved and CE-marked, ensuring its safety and efficacy in clinical settings. Nevisense has been utilized in over 300,000 patient tests globally, demonstrating its effectiveness in improving diagnostic accuracy and patient outcomes. The platform has evolved through several iterations, with Nevisense 3.0 offering a streamlined workflow and enhanced performance, and Nevisense V introducing an updated user interface and improved display resolution. Additionally, Nevisense has been adapted for research applications, such as assessing skin barrier function in atopic dermatitis studies. SciBase continues to advance Nevisense, aiming to expand its capabilities and applications in dermatology.","categories":["diagnostic Support","clinical Care","patient Facing","oncology Care","medical Device","ai Clinical Documentation Integrity","point-of-care","clinical Decision Support","Diagnostic","Clinical","Patient-facing","Dermatology","Oncology","Medical Device","Ai-powered","Non-invasive","Point-of-care","Skin Cancer Detection"],"market_segment":["enterprise","consumer","research","clinical","medical device"],"target_users":["clinicians","dermatologists","patients","researchers","healthcare providers","medical professionals"],"specialties":["Dermatology","Oncology","Skin Cancer","Melanoma","Non-melanoma Skin Cancer","Atopic Dermatitis","Skin Barrier Assessment"],"regions_available":["United States","Europe","Australia","Sweden","Germany","United Kingdom","France","Italy","Spain","Netherlands","Denmark","Norway","Finland","Switzerland","Austria","Belgium","Canada","Japan","South Korea","China"],"languages_supported":["English","Swedish","German","French","Italian","Spanish","Dutch","Danish","Norwegian","Finnish","Swiss German","Austrian German","Belgian Dutch","Canadian French","Japanese","Korean","Chinese"],"pricing_model":"enterprise_quote","pricing_details":"Contact vendor for pricing information.","license":"commercial","company_offices":["Sweden","United States","Germany","United Kingdom","France","Italy","Spain","Netherlands","Denmark","Norway"],"company_founding":"2000","deployment_model":["SaaS","on_prem","hybrid"],"os_platforms":["Web","iOS","Android","Windows","macOS","Linux"],"features":["Non-invasive melanoma detection","Skin barrier assessment","Atopic dermatitis evaluation","AI-driven diagnostic support","Electrical Impedance Spectroscopy (EIS) technology","Point-of-care testing","Clinical workflow integration","FDA-approved system","CE marked in Europe","TGA approval in Australia","MDR certified in Europe","Clinical studies supporting efficacy","User-friendly interface","Real-time results","Portable device design","Data storage and management","Patient data privacy compliance","Remote software updates","Multilingual support","Customizable reporting"],"optional_modules":["eBarrier Score for skin barrier assessment","Non-melanoma skin cancer (NMSC) application"],"integrations":["DermoGenius Ultra dermoscopy system","Electronic Medical Record (EMR) systems in Germany","Skinobs cosmetic testing platform","Al Shirawi Healthcare solutions in UAE"],"data_standards":["FHIR","HL7 v2","DICOM","SNOMED","ICD-10"],"api_available":"unknown","system_requirements":"Windows 10 or later, macOS 10.15 or later, iOS 12 or later, Android 9 or later","compliance":["HIPAA","GDPR","HITECH","SOC 2","ISO 27001","MDR","FDA 510(k)","CE/MDR","TGA","ISO 13485"],"certifications":["FDA 510(k)","CE/MDR","TGA","ISO 13485","MDR"],"security_features":["Encryption","RBAC","SSO/SAML","audit logs","2FA","DLP"],"privacy_features":["BAA available","consent mgmt","anonymization","data minimization"],"data_residency":"EU-only, US/EU regions, BYO cloud region","customers":["Over 300,000 patients tested with Nevisense"],"user_reviews":[],"ratings":[],"support_channels":[],"training_options":[],"release_year":"2015","integration_partners":[],"id":"SW0612","slug":"nevisense","type":"product","version":"1.0","last_updated":"2025-10-11","links_json":{"self":"https://www.healthaidb.com/software/nevisense.json"}}